Why It Matters
Medicare Part D plans generally did not cover over-the-counter naloxone nasal sprays in 2025, while Medicaid covered them in 2024, according to a Government Accountability Office (GAO) report on opioid overdose reversal medication coverage published Nov. 9.
GAO found that all Medicare Part D enrollees in 2025 and Medicaid enrollees in 2024 had coverage for at least one form of naloxone, including injectable versions. However, coverage of nalmefene, a newer and longer-acting overdose reversal medication, was less common.
The findings highlight differences in insurance coverage for medications that can prevent fatal opioid overdoses, particularly as more naloxone products become available without a prescription.
The Big Picture
Naloxone and nalmefene are two medications used to reverse opioid overdoses. Both are available as injections and nasal sprays, in generic and brand-name versions, while naloxone is also available in low and high doses. Low-dose naloxone nasal sprays have been available over the counter since 2023.
GAO said declining overdose deaths since 2023 "may have resulted in part from greater access" to these medications. However, the availability of over-the-counter versions has raised concerns among researchers because insurance plans may not cover medications sold without a prescription.
Congress asked GAO to examine coverage and out-of-pocket costs for people enrolled in Medicare Part D and Medicaid. The agency analyzed Centers for Medicare & Medicaid Services data for Medicare Part D in 2025 and Medicaid drug reimbursement records from all 50 states and the District of Columbia in 2024, the most recent data available at the time of the review.
GAO found that coverage varied significantly by medication and formulation. Although all enrollees had coverage for some form of naloxone, Medicare Part D plans generally did not cover over-the-counter nasal sprays, while Medicaid programs did. The report also identified limitations in its Medicaid findings. GAO counted states as covering a medication only when reimbursement records showed it had been used, meaning additional states may have offered coverage without recording any utilization.
To examine out-of-pocket costs, GAO interviewed representatives from four Medicare Part D plan sponsors selected from the eight largest by national market share and four state Medicaid programs selected for differences in overdose rates and geography. The agency cautioned that these selections were not nationally representative.
The Bottom Line
GAO made no recommendations in the report. The Department of Health and Human Services reviewed the findings and provided technical comments, which GAO incorporated as appropriate. The report found substantial differences in out-of-pocket costs depending on the medication, formulation, and insurance program.
For Medicare Part D enrollees, generic naloxone injections had the lowest median copays, ranging from $3 to $10. Brand-name high-dose naloxone and nalmefene nasal sprays carried some of the highest costs, with median coinsurance rates ranging from 25% to 35%. For a covered nasal spray costing $150, those coinsurance rates would leave an enrollee paying approximately $38 to $53 out of pocket.
Medicaid enrollees generally faced lower costs in the four states GAO examined. Two states charged no copays for overdose reversal medications, while the other two charged less than $5. The findings underscore how differences in Medicare and Medicaid coverage can affect what patients pay for lifesaving overdose reversal medications, even when both programs cover at least one form of naloxone.
A linked invitation to track related legislative activity on Legis1
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article